Investor Presentation - drreddys.com

1 Investor PresentationDr. Reddy s Laboratories LimitedHyderabad, IndiaBSE: 500124 | NSE: DRREDDY | NYSE: RDY February 2018 Safe Harbor StatementThis Presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as anticipates , believes , estimates , expects , intends , plans , predicts , projects and similar expressions.

2 Risks and uncertainties that could affect us include, without limitation: General economic and business conditions in India and other key global markets in which we operate; The ability to successfully implement our strategy, our research and development efforts, growth & expansion plans and technological changes; Changes in the value of the Rupee and other currency changes; Changes in the Indian and international interest rates; Allocations of funds by the Governments in our key global markets; Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry; Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry; and Changes in political conditions in India and in our key global one or more of such risks and uncertainties materialize, or should any underlying assumption prove incorrect, actual outcomes may vary materially from those indicated in the applicable forward-looking statements.

3 For more detailed information on the risks and uncertainties associated with the Company s business activities, please see the Company s Form 20-F for the fiscal year ended March 31, 2017, and Form 6-K for the quarters ended June 30, 2017, September 30, 2017 and December 31, 2017 and other filings with the US SEC. Any forward-looking statement or information contained in this Presentation speaks only as of the date of the statement. We are not required to update any such statement or information to either reflect events or circumstances that occur after the datethe statement or information is made or to account for unanticipated events2 ContentsOur PurposeCompany OverviewRecent Business HighlightsGrowth RoadmapOptimistic Future34 Bringing expensive medicine within reachAddressing unmet patient needsHelping patients manage disease betterEnabling and helping our partners ensure our medicines are available where neededOur Purpose Guides Our Customer Value Proposition Leading to Specific Strategic Choices5We accelerate access

4 Toaffordable medicinesbecauseGoodHealth Can PROMISESW orking with partners to help them succeedCOMPANY OVERVIEW6 CurrentMultidimensional business model to sustain long-term growth7 Future Leverage Industry leading chemistry skills to synthesize complex APIs enabling robust portfolio across the businessesUNBRANDED(US + EU)BRANDED(EM + INDIA)PROPRIETARY PRODUCTS Monetize the complex/ limited competition assets across channels and classes of trade Continued growth for mega brands through patient centric initiatives Selective business integration on NCE assets Maximize the base business revenues through volume growth initiatives and managed care strategy Accelerate Biosimilars filings in US and EU Outreach model for novel dosage forms in Non-traditional channels Accelerate the journey to monetize Biosimilars assets across existing and new markets Focus on development and filing of late-stage.

5 High-value differentiated assets PSAIKey strengths and capabilitiesIndustryleading product development skillsDeep market presenceEarly mover advantage in BiosimilarsCollaboration across business units Several niche product opportunities in USA market (liposomal doxorubicin, sevelamer carbonate, decitabine, azacitidine, metoprolol, fondaparinux) Branded generic markets -India, Russia, CIS and other countries Non-branded markets USA , UK, Germany and other countries First to launch Biosimilar rituximab in 2007 4 Biosimilar products being marketed, 2 in clinical development and 3 entering toxicology phase R&D centers in India, UK, Netherlands and USAV ertically integrated organization with modern infrastructure89Dr.

6 Reddy s Laboratories Ltd. Investor Presentation -2017 Formulation manufacturing infrastructure and capabilitiesDOSAGE FORMCAPABILITIESDETAILSOral Solids (22 bn pills annual)Tablets, Capsules, Pellets, bi-layers, Modified / Extended release, ODTs10 Facilities out of which 4 US FDA approved of which 2 are located in USA 3 MHRA approvedInjectable (110 mn units annual)Vial / PFS including complex products3 Facilities out of which 1 oncology facility, USFDA/MHRA/ANVISA approved 1 State of the art facility commissioned 1 facility approved by ANVISA/Romania focused on emerging marketsOintments (40 mn units annual)

7 Tubes/creams/ Gel2 Facilities out of which 1 facility for emerging and domestic market and 1 facility for US market recently operationalized and audited by US FDAM ultiple strategic alliances for manufacturing variety of dosage forms9 Product Development CentresHyderabad & BangaloreAurigene DiscoveryTechnologies LtdBangaloreGlobalized R&D to Access the Right Talent to Solve Complex Scientific ChallengesComplex Chemistry Centre of Excellence Cambridge, UKComplex Generics & Proprietary ProductsPrinceton, NJ, USAC omplex Injectable Centre of ExcellenceLeiden, NetherlandsExternal partnersCanadaUSAI talyGermanyUK10 Recent Business Highlights11 Delivering affordable generic alternatives in Unbranded Markets12 NEW PRODUCTS LAUNCHED INNORTH AMERICA SO FAR THIS FISCAL Sevelamer Carbonate Tablets launched in the Market Affordable alternative for complex, limited-competition product Fourth limited-competition launch this fiscal year (after Doxorubicin Hydrochloride Liposome Injection, Bivalirudin for Injection, and Ezetimibe & Simvastatin Tablets)

8 Other Product Launches in the Melphalan Hydrochloride 50mg Powder for Injection Clofarabine Injection for Intravenous Use Metaxalone Tablets Cefixime for Oral SuspensionPipeline Updates Positive DC outcome on Suboxone litigation Launch preparations on track for on near-term big-ticketlaunches On target for 20-25 filings this year11 Successful launches of Oncology products in EM and EU Colombia, Brazil, Algeria, Spain, ItalyBiosimilars and small molecule Oncology assets fueling global expansion13 Reditux paving the way for the entry of upcoming Biosimilar assets in new markets Currently approved in 17 countries and available in 14 Launched four products in India through strategic collaboration with AmgenEntry into more new markets in LatAm.

9 Africa and Asia slated for Q4 FY 18 / FY 19 Making a difference through Patient-centric Initiatives in Emerging Markets14 Push Tab feature in carton to serve as a reminder of when to have the medicineIntegrated flap that provides key information to the patientOur first wave of patient-centric packaging has been received well Four India Star awards for patient-centric packaging (selected from 622 entries); now qualify for Asia star and World star awards Positive feedback from patients, doctors and pharmacistsPrototyping packaging innovations for patients in Russia Working with Geriatric Society to enhance therapy experience of geriatric patients Revamping packaging of OTC brandsAdherence programs After success in specialty care, we now have achieved scale in primary care with the CVAD adherence program in India13 Commercial Updates First set of launches Zembrace and Sernivo ramping up well.

10 Continue to focus on accelerating the commercial business path to profitability Promius Pharma recognized as an emerging R&D driven commercial organizationin the neurology and dermatology communities R&D Updates Developing robust R&D Pipeline Four assetsin Phase III and Three assetsin Phase II respectivelyBD Updates Out-licensing of DFD-06, a topical high potency steroid, to Encore Dermatology Global License and Commercialization Agreement for Phase III Clinical Trial Candidate (DFA 02) for Mitigation of Surgical Site Infectionswith CHD BiosciencesAddressing unmet needs in Derma and Neurology15WE ARE COMMITTED TO EXCELLENCE IN QUALITY AND TO BEING THE BEST IN THE INDUSTRYOur Quality FDA Audit UpdatesSites Previously on Warning LetterFTO 3 Bachupally: Received EIRM irfield Plant: Concluded with three observationsMexico: Concluded with zero observationsCPS Technology Development Center: Concluded with zero observationsFTO SEZ PU 02: Received EIR FTO SEZ PU 01:Received EIR CTO 5: Three observations in audit -Received EIRCTO 6.